Journal of Blood Medicine

Dovepress
open access to scientific and medical research

Open Access Full Text Article

REVIEW

Telomere Dynamics in Sickle Cell Anemia: Unraveling Molecular Aging and Disease Progression

Emmanuel Ifeanyi Obeagu[1], Getrude Uzoma Obeagu[2]

[1]Department of Medical Laboratory Science, Kampala International University, Ishaka, Uganda; [2]School of Nursing Science, Kampala International University, Ishaka, Uganda

Correspondence: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, Email emmanuelobeagu@yahoo.com

Abstract: Sickle Cell Anemia (SCA) is a hereditary blood disorder characterized by the presence of abnormal hemoglobin, leading to the formation of sickle-shaped red blood cells. While extensive research has unraveled many aspects of the genetic and molecular basis of SCA, the role of telomere dynamics in disease progression remains a relatively unexplored frontier. This review seeks to provide a comprehensive examination of telomere biology within the context of SCA, aiming to elucidate its potential impact on molecular aging and the progression of the disease. The impact of oxidative stress on telomere dynamics in SCA is explored, with a particular focus on how increased reactive oxygen species (ROS) may contribute to accelerated telomere shortening and genomic instability. Furthermore, the potential relationship between telomere dysfunction and cellular senescence in SCA is investigated, shedding light on how telomere dynamics may contribute to the premature aging of cells in this population. The review concludes by summarizing key findings and proposing potential therapeutic strategies targeting telomere dynamics to mitigate disease progression in SCA. It also identifies gaps in current understanding and suggests avenues for future research, emphasizing the importance of further investigating telomere biology to advance our understanding of molecular aging and disease progression in Sickle Cell Anemia. This comprehensive exploration of telomere dynamics in SCA offers insights into potential mechanisms of molecular aging and disease progression, paving the way for targeted therapeutic interventions and improved disease management.

Keywords: sickle cell anemia, telomere, molecular aging, hemoglobinopathy, telomere shortening, oxidative stress

Introduction

Sickle Cell Anemia (SCA) stands as a paradigmatic hematological disorder, characterized by the abnormal production of hemoglobin and the consequential formation of sickle-shaped erythrocytes.[1–3] While advancements in genetic and molecular research have significantly enhanced our understanding of SCA, certain facets of its pathophysiology, particularly the role of telomere dynamics, remain relatively unexplored. Telomeres, protective nucleoprotein structures at the ends of chromosomes, play a crucial role in preserving genomic integrity and cellular function.[4] Given their significance in normal cellular processes, disruptions in telomere dynamics may have far-reaching consequences. This review endeavors to provide a comprehensive exploration of telomere biology within the context of SCA, aiming to unravel its potential implications for molecular aging and disease progression. Understanding the molecular intricacies of SCA, coupled with insights into telomere dynamics, holds the promise of shedding light on novel mechanisms influencing the course of the disease. SCA arises from a point mutation in the β-globin gene, leading to the synthesis of abnormal hemoglobin (HbS). The resultant sickle-shaped erythrocytes contribute to vaso-occlusive events, hemolysis, and a myriad of clinical complications. While much attention has been given to the genetic determinants and molecular events underpinning SCA, the impact of telomere dynamics on disease progression remains an area warranting exploration.[5,6] Telomere dysfunction has been implicated in various hematological and aging-related disorders. Understanding its role in SCA could provide novel insights into the molecular mechanisms driving the disease.[7] This review is prompted by the need to synthesize existing knowledge on telomere dynamics in SCA, elucidating their potential contribution to molecular aging and disease progression.

Received: 3 February 2024
Accepted: 23 July 2024
Published: 26 July 2024

Sickle Cell Anemia (SCA) is a complex disorder characterized by the presence of abnormal hemoglobin S, which leads to the sickling of red blood cells. This sickling process triggers a cascade of pathophysiological mechanisms including chronic hemolysis, vaso-occlusive events, and widespread inflammation. These processes impose considerable stress on various cell types, particularly hematopoietic stem cells (HSCs), which are responsible for the continuous replenishment of blood cells. The high turnover rate of these cells, combined with persistent oxidative stress and inflammatory signals, results in accelerated telomere shortening in individuals with SCA. Telomeres, which protect chromosome ends from deterioration, naturally shorten with each cell division. However, in SCA, this shortening is exacerbated, leading to premature cellular senescence or apoptosis, thereby contributing to the overall disease burden and progression. The advent of gene therapy for SCA holds significant promise in addressing telomere shortening-associated aging. By correcting the underlying genetic defect, gene therapy can potentially reduce the chronic hemolysis and inflammation that drive excessive cell turnover and oxidative stress. Consequently, this reduction could alleviate the accelerated telomere attrition observed in SCA patients. By stabilizing telomere length, gene therapy may not only improve hematopoietic stem cell function and longevity but also mitigate the premature aging and comorbidities associated with SCA. This therapeutic approach represents a transformative shift in managing SCA, offering hope for improved quality of life and prolonged health span for patients suffering from this debilitating condition.[2,3]

Recent advancements in gene therapy have ushered in a new era of potential treatments for Sickle Cell Anemia (SCA), offering hope for addressing the genetic root of this debilitating disease. Traditional therapies have primarily focused on managing symptoms and complications, but gene therapy aims to correct the underlying genetic defect, thereby altering the disease trajectory fundamentally. One of the most promising approaches involves using CRISPR-Cas9 technology to edit the HBB gene, thereby correcting the mutation responsible for the production of sickle hemoglobin. By targeting the source of hemoglobin abnormalities, gene therapy could significantly reduce hemolysis, inflammation, and oxidative stress—all of which are major contributors to telomere shortening in SCA patients. The potential impact of successful gene therapy on telomere dynamics in SCA patients could be profound. As gene therapy reduces the burden of sickled red blood cells, it is likely to decrease the chronic inflammatory state and oxidative damage that drive telomere attrition. Consequently, patients might experience a slowdown in the accelerated telomere shortening associated with SCA, potentially mitigating premature cellular aging and reducing the risk of age-related comorbidities. Additionally, by preserving telomere length, gene therapy could enhance the longevity and functionality of hematopoietic stem cells, thereby improving the overall hematopoietic system's resilience and reducing the frequency of complications such as vaso-occlusive crises. This could not only extend the lifespan of SCA patients but also significantly enhance their quality of life.[4–7]

Objectives

1. To provide a comprehensive overview of telomere structure, function, and dynamics.
2. To explore existing literature on normal telomere dynamics in healthy individuals.
3. To investigate and summarize evidence of altered telomere dynamics specific to SCA.
4. To assess the potential impact of telomere dysfunction on cellular senescence and disease progression in SCA.
5. To discuss therapeutic implications and identify potential avenues for future research.

A thorough understanding of telomere dynamics in SCA may offer new perspectives on the molecular underpinnings of the disease, paving the way for targeted therapeutic interventions and improved patient management. By bridging the knowledge gap between telomere biology and SCA, this review contributes to a broader comprehension of molecular aging and disease progression in this hematological disorder.

Telomere Structure and Function

Telomeres, the protective caps located at the ends of linear chromosomes, play a pivotal role in maintaining genomic stability and cellular function.[8] Composed of repetitive DNA sequences and associated proteins, telomeres safeguard chromosomal integrity, preventing degradation and end-to-end fusions. Telomeres consist of tandem repeats of a specific DNA sequence, typically TTAGGG in vertebrates.[9] These repeats form a protective overhang, often termed the G-rich

single-stranded 3' overhang, essential for telomere function. The unique composition of telomeric DNA distinguishes it from the coding regions of the genome. The shelterin complex, a group of six telomere-specific proteins (TRF1, TRF2, POT1, TIN2, TPP1, and RAP1), binds to telomeric DNA and orchestrates various functions.[10] TRF1 and TRF2 bind to double-stranded telomeric DNA, while POT1 binds to the single-stranded overhang. The complex collectively ensures telomere protection, regulation, and proper telomere length maintenance.

Telomerase is an enzymatic complex crucial for telomere maintenance.[11] Comprising a catalytic subunit (TERT) and an RNA template (TERC), telomerase extends telomeric DNA, compensating for the gradual loss during cellular replication.[12] While active in germ cells and certain stem cells, most somatic cells exhibit limited telomerase activity, contributing to telomere shortening with each cell division.

Telomeres act as a biological clock, determining the number of cell divisions a somatic cell can undergo. The gradual shortening of telomeres with each division culminates in cellular senescence or apoptosis. By preventing chromosomal end-to-end fusions, telomeres maintain genomic stability and integrity. Dysfunctional telomeres can lead to chromosomal aberrations and genomic instability.[8] Critically short telomeres activate DNA damage responses, leading to cellular senescence or apoptosis.[13] This serves as a protective mechanism against the propagation of damaged cells. Telomere shortening is an inherent consequence of cellular replication, occurring in the absence of sufficient telomerase activity.[14] Factors influencing telomere shortening include oxidative stress, inflammation, and environmental exposures. Telomere attrition contributes to the aging process and is implicated in age-related diseases. Dysfunctional telomeres are associated with various diseases, including certain cancers and hematological disorders.[15] Telomere dysfunction can promote genomic instability, contributing to the initiation and progression of diseases. Understanding telomere dynamics holds therapeutic potential. Strategies targeting telomerase activation or modulation, known as telomerase-based therapies, are under investigation for age-related diseases and conditions associated with telomere dysfunction.

Telomere Dynamics in Healthy Individuals

Telomere dynamics play a crucial role in maintaining cellular health and functionality. In healthy individuals, telomere length varies among cell types, tissues, and individuals.[16] While telomeres are generally shorter in somatic cells compared to germ cells, a dynamic equilibrium exists, ensuring cellular homeostasis. Genetic and environmental factors contribute to inter-individual differences in telomere length. Telomerase, the enzyme responsible for telomere elongation, is predominantly active during embryonic development, in stem cells, and in certain specialized cells. In healthy somatic cells, telomerase activity is typically limited, leading to gradual telomere shortening with each cell division.[17] The Hayflick limit, proposed by Leonard Hayflick, describes the phenomenon of cellular replicative senescence, wherein somatic cells reach a maximum number of divisions due to telomere shortening.[18] This process acts as a natural biological clock, regulating the lifespan of cells. Aging is associated with cumulative telomere shortening, reflecting the historical cellular divisions experienced by an individual's cells.[19] The gradual loss of telomeric DNA contributes to the aging process, impacting tissue functionality and overall health. Various lifestyle factors, including stress, physical activity, and diet, can influence telomere dynamics.[20] Chronic stress and unhealthy lifestyle choices may accelerate telomere shortening, while positive lifestyle modifications and stress management strategies have been associated with telomere preservation.

Stem cells, characterized by the ability to self-renew and differentiate into various cell types, possess unique telomere maintenance mechanisms.[21] The balance between telomere shortening and preservation is crucial for the sustained regenerative capacity of stem cells. Immune cells, especially lymphocytes, undergo dynamic changes in telomere length throughout an individual's life.[22] Telomere shortening in immune cells is associated with decreased immune function and increased susceptibility to infections in the elderly. Studies suggest gender differences in telomere length dynamics, with women generally exhibiting longer telomeres than men.[23–25] Hormonal influences and X-chromosome inactivation may contribute to these variations. Despite the inevitable telomere shortening associated with aging, healthy individuals maintain telomere homeostasis through a delicate balance between telomere attrition, telomerase activity, and cellular turnover.[26]

Telomere Shortening in Sickle Cell Anemia

Sickle Cell Anemia (SCA) is a hereditary hemoglobinopathy characterized by abnormal hemoglobin production, leading to the formation of sickle-shaped erythrocytes. While much attention has been devoted to the genetic aspects of SCA, the impact of telomere dynamics on disease progression remains a less-explored aspect.[27–29] Emerging evidence suggests that individuals with SCA may experience accelerated telomere shortening compared to healthy counterparts.[30] Factors contributing to this phenomenon include chronic hemolysis, increased oxidative stress, and the heightened inflammatory state characteristic of SCA. Hemolysis, a hallmark of SCA, results in the premature destruction of erythrocytes. The chronic turnover of red blood cells, compounded by the unique challenges presented by sickle-shaped cells, may contribute to accelerated telomere attrition in individuals with SCA.[31–33] The oxidative stress inherent in SCA, driven by the presence of abnormal hemoglobin and inflammatory processes, poses a potential link to telomere shortening.[34] Increased reactive oxygen species (ROS) generation may contribute to DNA damage, affecting telomeric regions. The chronic inflammatory state in SCA, triggered by recurrent vaso-occlusive events and endothelial dysfunction, could contribute to telomere dysfunction. Inflammatory mediators may influence telomerase activity and exacerbate telomere shortening.[35] The unique bone marrow environment in individuals with SCA, characterized by increased erythropoiesis and altered hematopoietic niches, may impact telomere dynamics.[36] The continuous demand for new erythrocytes may contribute to accelerated telomere attrition in hematopoietic stem cells.

Telomerase in Sickle Cell Anemia

Telomerase, a key enzyme responsible for maintaining telomere length, plays a critical role in cellular homeostasis.[37] In the context of Sickle Cell Anemia (SCA), understanding the dynamics of telomerase activity becomes essential due to the unique challenges posed by the disease. Most somatic cells exhibit limited telomerase activity, leading to gradual telomere shortening with each cell division.[38] Factors such as chronic hemolysis, oxidative stress, and inflammatory processes may influence the regulation of telomerase in SCA patients.[39] Given the elevated oxidative stress in SCA, this section delves into the potential influence of reactive oxygen species (ROS) on telomerase regulation. Oxidative stress is known to impact telomere dynamics, and understanding this interplay in SCA is essential. Inflammatory mediators may modulate the regulation of telomerase, influencing its function in SCA.

Oxidative Stress and Genomic Instability

Oxidative stress and genomic instability are interconnected processes that play crucial roles in various physiological and pathological conditions.[40] Oxidative stress occurs when there is an imbalance between the production of reactive oxygen species (ROS) and the body's ability to neutralize them through antioxidants.[41] Reactive oxygen species are generated during normal cellular metabolism, and their levels can increase due to factors such as environmental pollutants, radiation, inflammation, and certain drugs. Excessive ROS can damage cellular components, including lipids, proteins, and DNA, leading to disruptions in normal cell function and contributing to the development of various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases.[42] Genomic instability refers to an increased tendency for alterations in the DNA sequence, such as mutations, deletions, and chromosomal rearrangements.[43] Genomic instability can result from various factors, including errors during DNA replication, exposure to mutagenic agents (such as certain chemicals or radiation), and defects in DNA repair mechanisms. Genomic instability is a hallmark of cancer, as it can lead to the accumulation of genetic mutations that drive the uncontrolled growth of cells. ROS can directly damage DNA by causing modifications to its structure.[44] For example, they can induce base modifications and strand breaks. Oxidative stress can also interfere with the normal functioning of DNA repair mechanisms. If the repair processes are compromised, the likelihood of genomic instability increases. Genomic instability can further contribute to oxidative stress. Mutated or damaged cells may produce more ROS, creating a cycle of damage and instability. The link between oxidative stress and genomic instability is particularly relevant in cancer.[45] Genomic instability, often driven by oxidative damage, can contribute to the initiation and progression of cancer.[46] Both oxidative stress and genomic instability are associated with aging and age-related diseases, including neurodegenerative disorders.

Association with SCA Manifestations/Pathophysiology and Telomere Shortening Specifying the Mechanisms

The association between Sickle Cell Anemia (SCA) manifestations and telomere shortening is multifaceted, with various mechanisms intertwining to exacerbate the disease pathology. SCA is marked by chronic hemolysis and vaso-occlusive episodes, leading to continuous cycles of tissue ischemia and reperfusion. These pathological processes contribute significantly to oxidative stress, inflammation, and increased cellular turnover, all of which play pivotal roles in telomere shortening. Oxidative stress is a critical factor in telomere shortening within SCA. Due to recurrent hemolysis, free heme and iron are released into the circulation, catalyzing the formation of reactive oxygen species (ROS). ROS can cause direct damage to DNA, including telomeric regions, which are particularly susceptible to oxidative damage due to their high guanine content. This oxidative damage accelerates the shortening of telomeres, leading to premature cellular senescence and apoptosis. Chronic inflammation is another major contributor to telomere attrition in SCA. Persistent inflammatory responses are driven by ongoing tissue damage and the release of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukins (IL-1, IL-6). These cytokines promote the activation and proliferation of immune cells, particularly leukocytes. The increased turnover and proliferation rates of these cells lead to heightened telomere shortening. Additionally, inflammatory mediators can induce oxidative stress, further contributing to telomere erosion.[41–43]

In SCA, there is a marked increase in cellular turnover, particularly within the hematopoietic system. The chronic destruction of sickle-shaped erythrocytes necessitates constant replenishment from hematopoietic stem cells (HSCs). This relentless demand for new blood cells imposes significant replicative stress on HSCs, resulting in accelerated telomere shortening. Over time, this can lead to HSC exhaustion, diminishing the bone marrow's capacity to produce adequate blood cells and contributing to the anemia and other hematological abnormalities seen in SCA patients. Endothelial cells lining the blood vessels are also adversely affected by telomere shortening in SCA. The repetitive cycles of ischemia-reperfusion injury led to endothelial activation and dysfunction. Endothelial cells with critically short telomeres may become senescent or apoptotic, compromising vascular integrity and function. This dysfunction exacerbates the frequency and severity of vaso-occlusive crises, a hallmark of SCA. Telomere shortening has direct implications for various clinical manifestations of SCA. Shortened telomeres in HSCs and progenitor cells can lead to ineffective hematopoiesis, contributing to severe anemia and increased transfusion requirements. Furthermore, the premature aging of immune cells due to telomere attrition can impair immune responses, increasing susceptibility to infections. Vascular complications, such as pulmonary hypertension and chronic kidney disease, are also linked to telomere shortening through mechanisms involving endothelial dysfunction and vascular aging.[44,45]

Telomeres and Senescence in Sickle Cell Anemia

Telomeres and senescence are important cellular processes that can be relevant to the understanding of sickle cell anemia, a genetic disorder characterized by abnormal hemoglobin in red blood cells. Telomeres gradually shorten with each cell division, and when they become critically short, cells may enter a state of replicative senescence or undergo apoptosis (cell death).[47] In individuals with sickle cell anemia, red blood cells are prone to premature destruction (hemolysis), leading to a higher turnover of red blood cells. This increased turnover could potentially impact telomere length over time. Cellular senescence is a state in which cells cease to divide and undergo functional changes.[48] It can be triggered by various factors, including DNA damage, telomere shortening, and stress. The chronic nature of sickle cell anemia, characterized by recurrent episodes of vaso-occlusive crises and inflammation, may contribute to cellular stress and damage, potentially triggering senescence in various cell types.

The increased turnover of red blood cells in sickle cell anemia may contribute to telomere shortening over time, potentially affecting the lifespan of these cells.[49] The inflammatory nature of sickle cell anemia, coupled with oxidative stress, could contribute to cellular senescence in different tissues. Senescent cells may release pro-inflammatory signals, creating a feedback loop that exacerbates inflammation. Telomere shortening and cellular senescence may play roles in the overall pathophysiology of sickle cell anemia.[50] Premature aging of cells, particularly those involved in the immune response or tissue repair, could influence the severity and complications of the disease. Understanding the interplay

between telomeres, senescence, and sickle cell anemia may identify potential therapeutic targets. Strategies aimed at mitigating oxidative stress, inflammation, and improving cellular repair mechanisms could be explored.

Therapeutic Implications and Future Directions

Therapeutic implications for conditions involving oxidative stress, genomic instability, telomeres, senescence, and diseases like sickle cell anemia are broad and multifaceted.[51] Developing and utilizing antioxidant therapies to mitigate oxidative stress, which may help in conditions where ROS-induced damage is a significant factor.[52] Augmenting DNA repair mechanisms to address genomic instability.[53] Exploring interventions to maintain or lengthen telomeres to slow down cellular aging. Developing drugs to modulate senescence, either by promoting the clearance of senescent cells (senolysis) or altering the senescence-associated secretory phenotype (SASP).[54] Utilizing stem cell therapies to replace damaged or senescent cells and promote tissue regeneration.[55] Tailoring treatments based on the individual's genetic makeup, considering variations in genes related to oxidative stress response, DNA repair, telomere maintenance, and other relevant pathways.[56] Modulating the immune system to better respond to cellular damage and improve the clearance of damaged or senescent cells.[57] Promoting healthy lifestyles that include a balanced diet, regular exercise, and stress management to reduce the overall burden of oxidative stress and promote overall well-being. Continued development of advanced technologies such as gene editing (eg, CRISPR-Cas9) for precise modification of genes associated with these processes.[58,59]

Up-to-Date Knowledge and Approaches to Gene-Editing for Sickle Cell Anemia Treatment

Gene editing has emerged as a promising therapeutic approach for Sickle Cell Anemia (SCA), a genetic disorder caused by a mutation in the HBB gene encoding the beta-globin subunit of hemoglobin. This mutation leads to the production of abnormal hemoglobin S (HbS), causing red blood cells to become sickle-shaped and prone to hemolysis, leading to various complications. Recent advancements in gene-editing technologies, particularly CRISPR-Cas9, have opened new avenues for correcting the genetic defect at its source, offering potential cures for SCA.[58]

CRISPR-Cas9 Technology

CRISPR-Cas9 is a revolutionary gene-editing tool that allows for precise modifications of specific DNA sequences. In the context of SCA, CRISPR-Cas9 can be used to target and correct the HBB gene mutation or to induce the expression of fetal hemoglobin (HbF), which can ameliorate the disease symptoms.

1. **Direct Correction of HBB Mutation**: The CRISPR-Cas9 system can be designed to specifically target the mutant HBB gene and correct the single nucleotide mutation responsible for SCA. This approach involves the use of guide RNA (gRNA) to direct the Cas9 nuclease to the precise location of the mutation, where it introduces a double-strand break. The cell's repair mechanisms then use a supplied DNA template to repair the break, correcting the mutation and restoring normal beta-globin production.
2. **Induction of Fetal Hemoglobin (HbF)**: Another strategy leverages the natural protective effects of HbF, which inhibits HbS polymerization. CRISPR-Cas9 can be used to disrupt repressors of HbF expression, such as BCL11A or the HBG promoter regions. By knocking out these repressors, HbF levels can be increased, reducing the clinical severity of SCA.

Advances and Clinical Trials

Several clinical trials and preclinical studies have demonstrated the potential of CRISPR-Cas9-mediated gene editing for treating SCA. Notable examples include:

1. **CTX001 (CRISPR Therapeutics and Vertex Pharmaceuticals)**: CTX001 is an investigational therapy that uses CRISPR-Cas9 to edit the BCL11A gene in patients' hematopoietic stem cells (HSCs). By knocking out BCL11A,

the expression of HbF is reactivated. Early clinical trial results have shown promising outcomes, with treated patients exhibiting increased HbF levels and reduced SCA symptoms.

2. **Other Clinical Trials**: Several other clinical trials are underway, exploring various strategies for gene editing in SCA. These include approaches to directly correct the HBB mutation or enhance HbF production through different targets and delivery methods.

While gene editing offers exciting prospects, it also raises important safety and ethical considerations. Off-target effects, where unintended genetic modifications occur, are a primary concern. Ensuring the specificity and accuracy of gene-editing tools is crucial to minimize potential risks. Additionally, long-term monitoring of patients is necessary to assess the durability and safety of the edited cells. Ethical considerations include ensuring equitable access to these advanced therapies and addressing potential socio-economic disparities. Furthermore, informed consent and the ethical implications of germline editing, though not currently a focus for SCA, require careful consideration. The future of gene editing for SCA is promising, with ongoing research aimed at improving the efficiency, safety, and accessibility of these therapies. Innovations such as base editing and prime editing offer even more precise genetic modifications with potentially fewer off-target effects. Additionally, advancements in delivery methods, such as nanoparticles and viral vectors, are being explored to enhance the efficacy of gene-editing therapies. Combining gene editing with other therapeutic approaches, such as gene therapy and small molecule drugs, may also enhance treatment outcomes. Personalized medicine, where gene-editing strategies are tailored to individual patients' genetic profiles, represents another exciting frontier.[58,59]

Fresh Perspectives and Significant New Contributions to Gene-Editing for Sickle Cell Anemia

Recent advancements in gene-editing technologies have revolutionized the landscape of therapeutic options for Sickle Cell Anemia (SCA). While CRISPR-Cas9 has been the centerpiece of these innovations, newer approaches and insights are continually emerging, pushing the boundaries of what is possible in treating this debilitating genetic disorder. Here, we explore fresh perspectives and significant contributions that are shaping the future of gene-editing therapies for SCA.[2]

Base Editing: Precision Without Double-Strand Breaks

One of the most significant new contributions to gene-editing technology is the development of base editing. Unlike CRISPR-Cas9, which relies on creating double-strand breaks in DNA to induce repair mechanisms, base editors directly convert one nucleotide to another without making double-strand breaks. This method greatly reduces the risk of off-target effects and unwanted mutations.

1. **Adenine Base Editors (ABEs)**: ABEs convert adenine-thymine (A-T) base pairs to guanine-cytosine (G-C) base pairs. In the context of SCA, ABEs can precisely correct the single nucleotide mutation from adenine to thymine in the HBB gene that causes the production of HbS. This approach offers a safer and potentially more efficient method for correcting the genetic defect in SCA patients.
2. **Cytosine Base Editors (CBEs)**: Similarly, CBEs convert cytosine-guanine (C-G) base pairs to thymine-adenine (T-A) base pairs. While ABEs are directly relevant for SCA mutation correction, CBEs can be instrumental in other genetic modifications needed for SCA therapy, such as silencing repressor genes of fetal hemoglobin.[58]

Prime Editing: Versatility and Precision

Prime editing represents another groundbreaking advancement in the gene-editing field. This technology combines the specificity of CRISPR-Cas9 with a reverse transcriptase to directly write new genetic information into a target site, enabling a wide range of genetic alterations, including all possible base-to-base conversions, small insertions, and deletions.[59]

1. **Application in SCA**: Prime editing can be employed to correct the SCA mutation by precisely converting the abnormal thymine to adenine in the HBB gene. Its versatility allows for more complex genetic edits, which can be beneficial in addressing the heterogeneity of genetic mutations in SCA and potentially correcting multiple genetic defects in a single therapeutic intervention.

Enhancing Delivery Methods: Non-Viral Vectors and Nanoparticles

The delivery of gene-editing tools into patient cells, particularly hematopoietic stem cells (HSCs), is a critical challenge. Recent innovations in delivery methods are poised to significantly improve the efficiency and safety of gene-editing therapies.

1. **Non-Viral Vectors**: Advances in non-viral delivery systems, such as electroporation and lipid nanoparticles, are reducing the reliance on viral vectors, which can have immunogenicity and integration-related risks. These non-viral methods can offer safer and more controllable delivery of gene-editing components into HSCs.
2. **Nanoparticle Delivery**: Nanoparticles designed to encapsulate and protect CRISPR-Cas9 components are being optimized for efficient delivery into target cells. These nanoparticles can improve the precision of gene-editing tools, enhance cellular uptake, and minimize off-target effects by ensuring that the gene-editing components are delivered directly to the desired cellular compartments.

Synthetic Biology and Gene Circuits

Synthetic biology approaches, including the design of gene circuits, are contributing novel ways to regulate gene expression and enhance the safety of gene-editing therapies.

1. **Programmable Gene Circuits**: These circuits can be designed to regulate the expression of therapeutic genes in response to specific cellular signals or environmental cues. In SCA, programmable gene circuits can be used to control the expression of fetal hemoglobin or other therapeutic genes in a precise, context-dependent manner, enhancing the efficacy and safety of the treatment.
2. **Safety Switches**: Incorporating safety switches into gene-editing constructs allows for the controlled activation or deactivation of the gene-editing machinery. This innovation can mitigate potential adverse effects by enabling clinicians to turn off the gene-editing process if unintended consequences arise, thereby improving the overall safety profile of the therapy.

Ethical and Socioeconomic Considerations

Addressing the ethical and socioeconomic challenges associated with gene-editing therapies is a crucial aspect of advancing the field.

1. **Equitable Access**: Ensuring that these cutting-edge treatments are accessible to all patients, regardless of socio-economic status, is essential. This involves developing cost-effective manufacturing processes, creating scalable delivery systems, and implementing policies that promote equitable distribution.
2. **Informed Consent and Public Engagement**: Engaging with the public and ensuring informed consent are vital for the ethical deployment of gene-editing therapies. Clear communication about the risks, benefits, and long-term implications of gene-editing treatments can foster public trust and support for these innovative therapies.

Conclusion

Telomere dynamics play a critical role in the pathophysiology of sickle cell anemia (SCA), influencing both disease progression and the molecular aging process. The accelerated telomere shortening observed in SCA patients, driven by oxidative stress, chronic inflammation, and DNA damage, contributes to the severity of the disease and its complications. Shortened telomeres are associated with increased frequency of vaso-occlusive crises, severe anemia, and early onset of organ damage, making telomere length a potential prognostic marker for disease severity and progression. Interventions

aimed at reducing oxidative stress and inflammation, enhancing DNA repair mechanisms, and potentially activating telomerase could help preserve telomere length and improve clinical outcomes for SCA patients. Additionally, monitoring telomere length could provide valuable insights into disease progression and aid in the personalization of treatment plans.

Abbreviations

SCA, Sickle Cell Anemia; ROS, reactive oxygen species; SASP, senescence-associated secretory phenotype.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Obeagu EI, Ubosi NI, Obeagu GU, Egba SI, Bluth MH. Understanding apoptosis in sickle cell anemia patients: mechanisms and implications. *Medicine*. 2024;103(2):e36898. PMID: 38215146; PMCID: PMC10783340. doi:10.1097/MD.0000000000036898
2. Obeagu EI. Maximizing longevity: erythropoietin's impact on sickle cell anaemia survival rates. *Ann Med Surg Lond*. 2024;86(3):1570–1574. PMID: 38463100; PMCID: PMC10923353. doi:10.1097/MS9.0000000000001763
3. Obeagu EI, Obeagu GU. Malnutrition in sickle cell anemia: prevalence, impact, and interventions: a Review. *Medicine*. 2024;103(20):e38164. PMID: 38758879; PMCID: PMC11098235. doi:10.1097/MD.0000000000038164
4. Bettin N, Oss Pegorar C, Cusanelli E. The emerging roles of TERRA in telomere maintenance and genome stability. *Cells*. 2019;8(3):246. doi:10.3390/cells8030246
5. Obeagu EI, Obeagu GU. Management of diabetes mellitus patients with sickle cell anemia: challenges and therapeutic approaches. *Medicine*. 2024;103(17):e37941. PMID: 38669382; PMCID: PMC11049766. doi:10.1097/MD.0000000000037941
6. Obeagu EI, Obeagu GU, Akinleye CA, Igwe MC. Nosocomial infections in sickle cell anemia patients: prevention through multi-disciplinary approach: a review. *Medicine*. 2023;102(48):e36462. PMID: 38050205; PMCID: PMC10695528. doi:10.1097/MD.0000000000036462
7. Zhang H, Liesveld JL, Calvi LM, et al. The roles of bone remodeling in normal hematopoiesis and age-related hematological malignancies. *Bone Res*. 2023;11(1):15. doi:10.1038/s41413-023-00249-w
8. O'sullivan RJ, Karlseder J. Telomeres: protecting chromosomes against genome instability. *Nat Rev Mol Cell Biol*. 2010;11(3):171–181. doi:10.1038/nrm2848
9. Bolzán AD. Interstitial telomeric sequences in vertebrate chromosomes: origin, function, instability and evolution. *Mutat Res/Rev Mutat Res*. 2017;773:51–65. doi:10.1016/j.mrrev.2017.04.002
10. Mir SM, Samavarchi Tehrani S, Goodarzi G, et al. Shelterin complex at telomeres: implications in ageing. *Clin Interventions Aging*. 2020; Volume 15:827–839. doi:10.2147/CIA.S256425
11. Giardini MA, Segatto M, Da Silva MS, Nunes VS, Cano MI. Telomere and telomerase biology. *Progr Molecul Biol Translat Sci*. 2014;125:1–40.
12. Wu RA, Upton HE, Vogan JM, Collins K. Telomerase mechanism of telomere synthesis. *Annu Rev Biochem*. 2017;86:439–460. doi:10.1146/annurev-biochem-061516-045019
13. Fumagalli M, Rossiello F, Clerici M, et al. Telomeric DNA damage is irreparable and causes persistent DNA-damage-response activation. *Nat Cell Biol*. 2012;14(4):355–365. doi:10.1038/ncb2466
14. Lin J, Epel E. Stress and telomere shortening: insights from cellular mechanisms. *Ageing Res Rev*. 2022;73:101507. doi:10.1016/j.arr.2021.101507
15. Fiorini E, Santoni A, Colla S. Dysfunctional telomeres and hematological disorders. *Differentiation*. 2018;100:1. doi:10.1016/j.diff.2018.01.001
16. Monaghan P, Eisenberg DT, Harrington L, Nussey D. Understanding diversity in telomere dynamics. *Philos Trans R Soc B*. 2018;373 (1741):20160435. doi:10.1098/rstb.2016.0435
17. Lupatov AY, Yarygin KN. Telomeres and Telomerase in the Control of Stem Cells. *Biomedicines*. 2022;10(10):2335. doi:10.3390/biomedicines10102335
18. Chan M, Yuan H, Soifer I, et al. Novel insights from a multiomics dissection of the Hayflick limit. *Elife*. 2022;11:e70283. doi:10.7554/eLife.70283
19. Razgonova MP, Zakharenko AM, Golokhvast KS, et al. Telomerase and telomeres in aging theory and chronographic aging theory. *Molecul Med Rep*. 2020;22(3):1679–1694. doi:10.3892/mmr.2020.11274
20. Davinelli S, De Vivo I. Lifestyle choices, psychological stress and their impact on ageing: the role of telomeres. *Centenarians*. 2019;2019:135–148.
21. Batista LF. Telomere biology in stem cells and reprogramming. *Progr Molecul Biol Translat Sci*. 2014;125:67–88.
22. Effros RB. Telomere/telomerase dynamics within the human immune system: effect of chronic infection and stress. *Exp Gerontology*. 2011;46(2–3):135–140. doi:10.1016/j.exger.2010.08.027
23. Dalgård C, Benetos A, Verhulst S, et al. Leukocyte telomere length dynamics in women and men: menopause vs age effects. *Int J Epidemiol*. 2015;44(5):1688–1695. doi:10.1093/ije/dyv165
24. Gardner M, Bann D, Wiley L, et al. Gender and telomere length: systematic review and meta-analysis. *Exp Gerontology*. 2014;51:15–27. doi:10.1016/j.exger.2013.12.004
25. Mayer S, Brüderlein S, Perner S, et al. Sex-specific telomere length profiles and age-dependent erosion dynamics of individual chromosome arms in humans. *Cytogen Genome Res*. 2006;112(3–4):194–201. doi:10.1159/000089870
26. Aubert G, Lansdorp PM. Telomeres and aging. *Physiol Rev*. 2008;88(2):557–579. doi:10.1152/physrev.00026.2007
27. Dilli PP, Obeagu E, Tamale A, Ajugwo A, Pius T, Makeri D. Update on the practice of premarital screening for sickle cell traits in Africa: a systematic review and meta-analysis. *BMC Public Health*. 2024;24(1):1467. PMID: 38822327; PMCID: PMC11143629. doi:10.1186/s12889-024-19001-y

28. Obeagu EI, Obeagu GU. Managing gastrointestinal challenges: diarrhea in sickle cell anemia. *Medicine*. 2024;103(18):e38075. PMID: 38701274; PMCID: PMC11062666. doi:10.1097/MD.0000000000038075
29. Obeagu EI, Obeagu GU. Implications of climatic change on sickle cell anemia: a review. *Medicine*. 2024;103(6):e37127. PMID: 38335412; PMCID: PMC10860944. doi:10.1097/MD.0000000000037127
30. Bizarro J, Bhardwaj A, Smith S, Meier UT. Nopp140-mediated concentration of telomerase in Cajal bodies regulates telomere length. *?mol Biol Cell*. 2019;30(26):3136–3150. doi:10.1091/mbc.E19-08-0429
31. Obeagu EI. Eosinophilic dialogues: a molecular exploration of sickle cell anemia severity. *Ann Med Surg*. 2024;2024:10–97.
32. Drašar ER, Jiang J, Gardner K, et al. Leucocyte telomere length in patients with sickle cell disease. *Br J Haematol*. 2014;165(5):725–727. PMID: 24666270. doi:10.1111/bjh.12776
33. Mekontso Dessap A, Cecchini J, Chaar V, et al. Telomere attrition in sickle cell anemia. *Am J Hematol*. 2017;92(6):E112–E114. PMID: 28295518. doi:10.1002/ajh.24721
34. Cianflone E, Torella M, Biamonte F, et al. Targeting cardiac stem cell senescence to treat cardiac aging and disease. *Cells*. 2020;9(6):1558. doi:10.3390/cells9061558
35. Suliman ME, Ansari MGA, Rayis MA, et al. Telomere length and telomere repeat-binding protein in children with sickle cell disease. *Pediatr Res*. 2022;91(3):539–544. PMID: 33824452; PMCID: PMC8904250. doi:10.1038/s41390-021-01495-6
36. Thongon N, Ma F, Santoni A, et al. Hematopoiesis under telomere attrition at the single-cell resolution. *Nat Commun*. 2021;12(1):6850. doi:10.1038/s41467-021-27206-7
37. Fernandes SG, Dsouza R, Khattar E. External environmental agents influence telomere length and telomerase activity by modulating internal cellular processes: implications in human aging. *Environ Toxicol Pharmacol*. 2021;85:103633. doi:10.1016/j.etap.2021.103633
38. Shay JW. Role of telomeres and telomerase in aging and cancer. *Cancer Discovery*. 2016;6(6):584–593. doi:10.1158/2159-8290.CD-16-0062
39. Gorur V, Kranc KR, Ganuza M, Telfer P. Haematopoietic stem cell health in sickle cell disease and its implications for stem cell therapies and secondary haematological disorders. *Blood Rev*. 2023;63:101137. doi:10.1016/j.blre.2023.101137
40. Fakouri NB, Hou Y, Demarest TG, et al. Toward understanding genomic instability, mitochondrial dysfunction and aging. *FEBS J*. 2019;286 (6):1058–1073. doi:10.1111/febs.14663
41. Adwas AA, Elsayed A, Azab AE, Quwaydir FA. Oxidative stress and antioxidant mechanisms in human body. *J Appl Biotechnol Bioeng*. 2019;6 (1):43–47.
42. Juan CA, de la Lastra JM P, Plou FJ, Pérez-Lebeña E. The chemistry of reactive oxygen species (ROS) revisited: outlining their role in biological macromolecules (DNA, lipids and proteins) and induced pathologies. *Int J Mol Sci*. 2021;22(9):4642. doi:10.3390/ijms22094642
43. Colnaghi R, Carpenter G, Volker M, O'Driscoll M. The consequences of structural genomic alterations in humans: genomic disorders, genomic instability and cancer. *Semin Cell Dev Biol*. 2011;22(8):875–885. doi:10.1016/j.semcdb.2011.07.010
44. Huang Z, Chen Y, Zhang Y. Mitochondrial reactive oxygen species cause major oxidative mitochondrial DNA damages and repair pathways. *J Biosci*. 2020;45:1–7. doi:10.1007/s12038-020-00055-0
45. Ferguson LR, Chen H, Collins AR, et al. Genomic instability in human cancer: molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. *Semi Cancer Biol*. 2015;35:S5–S24. doi:10.1016/j.semcancer.2015.03.005
46. Tubbs A, Nussenzweig A. Endogenous DNA damage as a source of genomic instability in cancer. *Cell*. 2017;168(4):644–656. doi:10.1016/j.cell.2017.01.002
47. Victorelli S, Passos JF. Telomeres and cell senescence-size matters not. *EBioMedicine*. 2017;21:14–20. doi:10.1016/j.ebiom.2017.03.027
48. Ben-Porath I, Weinberg RA. When cells get stressed: an integrative view of cellular senescence. *J Clin Invest*. 2004;113(1):8–13. doi:10.1172/JCI200420663
49. Colella MP, Santana BA, Conran N, et al. Telomere length correlates with disease severity and inflammation in sickle cell disease. *Rev Brasil de Hematol Hemoterap*. 2017;39(2):140–145. doi:10.1016/j.bjhh.2017.02.007
50. Idris IM, Botchwey EA, Hyacinth HI. Sickle cell disease as an accelerated aging syndrome. *Exp Biol Med*. 2022;247(4):368–374. doi:10.1177/15353702211068522
51. Kapor S, Čokić V, Santibanez JF. Mechanisms of hydroxyurea-induced cellular senescence: an oxidative stress connection? *Oxid Med Cell Longev*. 2021;1–6. doi:10.1155/2021/7753857
52. Farías JG, Molina VM, Carrasco RA, et al. Antioxidant therapeutic strategies for cardiovascular conditions associated with oxidative stress. *Nutrients*. 2017;9(9):966. doi:10.3390/nu9090966
53. Zong C, Zhu T, He J, Huang R, Jia R, Shen J. PARP mediated DNA damage response, genomic stability and immune responses. *Internat J Can*. 2022;150(11):1745–1759. doi:10.1002/ijc.33918
54. Chambers CR, Ritchie S, Pereira BA, Timpson P. Overcoming the senescence-associated secretory phenotype (SASP): a complex mechanism of resistance in the treatment of cancer. *Mol Oncol*. 2021;15(12):3242–3255. doi:10.1002/1878-0261.13042
55. Turinetto V, Vitale E, Giachino C. Senescence in human mesenchymal stem cells: functional changes and implications in stem cell-based therapy. *Int J Mol Sci*. 2016;17(7):1164. doi:10.3390/ijms17071164
56. Muresanu C, Somasundaram SG, Vissarionov SV, et al. Updated understanding of cancer as a metabolic and telomere-driven disease, and proposal for complex personalized treatment, a hypothesis. *Int J Mol Sci*. 2020;21(18):6521. doi:10.3390/ijms21186521
57. Prata LG, Ovsyannikova IG, Tchkonia T, Kirkland JL. Senescent cell clearance by the immune system: emerging therapeutic opportunities. *Semin Immunopathol*. 2018;40:101275. doi:10.1016/j.smim.2019.04.003
58. Arora L, Narula A. Gene editing and crop improvement using CRISPR-Cas9 system. *Front Plant Sci*. 2017;8:1932. doi:10.3389/fpls.2017.01932
59. Singh V, Gohil N, Ramirez Garcia R, Braddick D, Fofié CK. Recent advances in CRISPR-Cas9 genome editing technology for biological and biomedical investigations. *J Cell Biochem*. 2018;119(1):81–94. doi:10.1002/jcb.26165